Bioequivalence and Food Effect Assessment Between 2 Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Chinese Subjects
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1511 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Kaixian Tang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Trial Center, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Factor Xa Inhibitors, Food-Drug Interactions, Rivaroxaban. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
To evaluate the bioequivalence and safety of oral rivaroxaban tablets between a test formulation and a reference formulation in healthy Chinese subjects, a randomized, open, 2‐formulation, 4‐cycle, complete repeat crossover study was conducted under both fasting and fed states. Thirty‐six healthy participants were enrolled separately for the fasting and fed groups, and each subject received a single oral dose of 20 mg of the test or reference formulation of rivaroxaban tablets per cycle. Blood samples were collected at specified intervals, and rivaroxaban was analyzed using liquid chromatography–tandem mass spectrometry. Under fasting and fed conditions, the 90% confidence intervals (CIs) for the geometric mean ratios of the maximum concentration (C max ), the area under the plasma concentration–time curve from time 0 to the last measurable time point (AUC 0‐t ), and the area under the curve extrapolated to infinity from time 0 (AUC 0‐∞ ) all fell within the 80%‐125% CI, and the upper limit of the 90% CIs for the test‐to‐reference ratio of the within‐subject variability was
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Trial Center, Huzhou Central Hospital, Fifth School of Clinical Medicine of Zhejiang Chinese Medical University, Huzhou, Zhejiang, China.
- Suzhou Dawnrays Pharmaceutical Co., Ltd, Suzhou, Jiangsu, China.
Zitieren
APA
Tang, K., Chen, Y., Mei, J., Bo, H., Liu, Q., Wang, W., Xu, M., Jin, Q., & Yang, S. (2025). Bioequivalence and Food Effect Assessment Between 2 Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1511
Vancouver
Tang K, Chen Y, Mei J, Bo H, Liu Q, Wang W, et al. Bioequivalence and Food Effect Assessment Between 2 Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Chinese Subjects. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1511
BibTeX
@article{Tang2025,
author = {Tang, Kaixian and Chen, Yingrong and Mei, Jue and Bo, Hui and Liu, Qing and Wang, Wei and Xu, Min and Jin, Qiuyue and Yang, Shuixin},
title = {Bioequivalence and Food Effect Assessment Between 2 Oral Tablet Formulations of Rivaroxaban 20 mg in Healthy Chinese Subjects},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1511}
}
EUVIMED